ResearcherNorth Dakota State UniversityActive in the last 2 years
Buddhadev Layek
Matched on ORCID iD 0000-0002-2457-7619; OpenAlex author ID A5003571906; NIH RePORTER profile ID 14882821. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 0, last author 4)
- Trials
- 0
- Grants
- 1
- Labs led
- 1
- Collaborators
- 25
2024: 2 papers · 2025: 2 papers · 2026: 1 paper, 1 grant
Papers 5
- Mesenchymal Stem Cell Exosome-Mediated Delivery of Paclitaxel for Pancreatic Cancer Therapy. Last author DOI 10.3390/biom16020269↗
- Co-treatment of ticagrelor and anti-PD-1 immunotherapy in tumor-associated macrophages reduces pancreatic cancer cell growth and migration through the TGF-β1/S… Co-author DOI 10.1016/j.biopha.2025.118695↗
- Panobinostat-Loaded Albumin Nanoparticles for the Treatment of Pancreatic Cancer. Last author DOI 10.1016/j.jddst.2025.107341↗
- Nanocarrier mediated entinostat and oxaliplatin combination therapy displayed enhanced efficacy against pancreatic cancer. Last author DOI 10.1016/j.biopha.2024.116743↗
- Mesenchymal stem cell-delivered paclitaxel nanoparticles exhibit enhanced efficacy against a syngeneic orthotopic mouse model of pancreatic cancer. Last author DOI 10.1016/j.ijpharm.2024.124753↗
Grants 1
Closest collaborators
The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Paras Mani Giri · 4 shared papers, 2024–2026 · strength 1.22
- Paper Panobinostat-Loaded Albumin Nanoparticles for the Treatment of Pancreatic Cancer. DOI 10.1016/j.jddst.2025.107341↗
- Paper Mesenchymal Stem Cell Exosome-Mediated Delivery of Paclitaxel for Pancreatic Cancer Therapy. DOI 10.3390/biom16020269↗
- Paper Mesenchymal stem cell-delivered paclitaxel nanoparticles exhibit enhanced efficacy against a syngeneic orthotopic mouse… DOI 10.1016/j.ijpharm.2024.124753↗
- Katie M. Reindl · 2 shared papers, 1 shared grant, 2024–2026 · strength 0.96
- Grant Biostatistics and Bioinformatics Core Facility P20GM109024↗
- Paper Mesenchymal stem cell-delivered paclitaxel nanoparticles exhibit enhanced efficacy against a syngeneic orthotopic mouse… DOI 10.1016/j.ijpharm.2024.124753↗
- Paper Nanocarrier mediated entinostat and oxaliplatin combination therapy displayed enhanced efficacy against pancreatic canc… DOI 10.1016/j.biopha.2024.116743↗
- Yongki Choi · 1 shared paper, 1 shared grant, 2026 · strength 0.82
- Elisabetta Liverani · 1 shared paper, 1 shared grant, 2025–2026 · strength 0.73
- Sanku Mallik · 1 shared paper, 1 shared grant, 2024–2026 · strength 0.70
- Anurag Banerjee · 2 shared papers, 2024–2026 · strength 0.61
- Philip Salu · 2 shared papers, 2024 · strength 0.50
- Paper Mesenchymal stem cell-delivered paclitaxel nanoparticles exhibit enhanced efficacy against a syngeneic orthotopic mouse… DOI 10.1016/j.ijpharm.2024.124753↗
- Paper Nanocarrier mediated entinostat and oxaliplatin combination therapy displayed enhanced efficacy against pancreatic canc… DOI 10.1016/j.biopha.2024.116743↗
- Sathish Venkatachalem · 1 shared grant, 2026 · strength 0.46
- Jiha Kim · 1 shared grant, 2026 · strength 0.46
- Megan Orr · 1 shared grant, 2026 · strength 0.46
- Mohiuddin Quadir · 1 shared grant, 2026 · strength 0.46
- Ang Guo · 1 shared grant, 2026 · strength 0.46
- Mark T Hamann · 1 shared grant, 2026 · strength 0.46
- Roberto Gomes · 1 shared grant, 2026 · strength 0.46
- Jagdish Singh · 1 shared grant, 2026 · strength 0.46
- Estelle Leclerc · 1 shared grant, 2026 · strength 0.46
- John Curlee Wilkinson · 1 shared grant, 2026 · strength 0.46
- Erxi Wu · 1 shared grant, 2026 · strength 0.46
- Bin Guo · 1 shared grant, 2026 · strength 0.46
- Guodong Liu · 1 shared grant, 2026 · strength 0.46
- Rick J. Jansen · 1 shared grant, 2026 · strength 0.46
- Ying Kang · 1 shared paper, 2025 · strength 0.27
- Marina Pasca di Magliano · 1 shared paper, 2025 · strength 0.27
- Michael Anthony Hollingsworth · 1 shared paper, 2025 · strength 0.27
- Paul M. Grandgenett · 1 shared paper, 2025 · strength 0.27
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.